Dr. Abate‐Daga completed his undergraduate studies in clinical biochemistry at the Universidad Nacional de Córdoba (Argentina), and his PhD in Health and Life Sciences at the Pompeu Fabra University and Centre for Genomic Regulation (Barcelona, Spain). He completed post doctorate training in cancer immunotherapy and gene therapy, under the mentorship of Dr. Steve Rosenberg, at the Surgery Branch of the National Institutes of Health. He then joined Moffitt Cancer Center in the summer of 2015, as an Assistant Member of the Department of Immunology.
Studying the molecular events that govern the correct function of genetically-modified human T cells, Dr. Abate-Daga combines technologies and expertise gathered from various fields, including systems biology, synthetic biology, basic immunology, and genomics, among others. His group is interested in understanding how a new generation of immune receptors (Chimeric Antigen Receptors, conventional T-cell receptors, and others) can be designed to outperform the current products, in both antitumor efficacy and safety. Dr. Abate-Daga’s team is also interested in identifying novel targets for cancer therapy, and in taking advantage of the unique biological properties of gamma/delta T cells for the treatment of various solid tumors.
Dr. Abate-Daga is the author of 24 peer-reviewed original manuscripts and book chapters that have been published in journals such as the J. Clinical Oncology, Blood, Clinical Cancer Research, Molecular Therapy, Human Gene Therapy, and Oncoimmunology, among others. In addition, he has served as ad hoc reviewer for various scientific publications, including Scientific Reports, New Journal of Science, Molecular Therapy, and Neoplasia. Dr. Abate-Daga has been the recipient of NIH Skin SPORE Career Enhancement Program and Developmental Research Program Awards. Dr. Abate-Daga has been invited to present in multiple research forums, including the Canadian Cancer Immunotherapy Consortium (Montreal, Canada), the World Preclinical Congress (Boston, MA), the conference on New Frontiers in Urologic Oncology (Clearwater, FL), the National Center for Tumor Disease (Heidelberg, Germany), and the Institut d’Investigacions Biomediques August Pi i Sunyer (Barcelona, Spain), among others.
